Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Deuruxolitinib - Concert Pharmaceuticals

Drug Profile

Deuruxolitinib - Concert Pharmaceuticals

Alternative Names: C-21543 phosphate; CTP-543; CTP-543 phosphate; D8- ruxolitinib phosphate; D8-ruxolitinib; Deuruxolitinib phosphate; Deuterated ruxolitinib; Deuterium ruxolitinib analogue; Ruxolitinib deuterated - Concert Pharmaceuticals

Latest Information Update: 14 May 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Concert Pharmaceuticals
  • Class 2 ring heterocyclic compounds; Cyclopentanes; Nitriles; Organic deuterium compounds; Pyrazoles; Pyrimidines; Pyrroles; Skin disorder therapies; Small molecules
  • Mechanism of Action Janus kinase 1 inhibitors; Janus kinase-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Alopecia areata

Most Recent Events

  • 08 Mar 2024 Efficacy data from the phase III THRIVE-AA2 trial in Alopecia areata were presented at the American Academy of Dermatology annual Meeting 2024 (AAD-2024)
  • 05 Dec 2023 Aclaris Therapeutics enters into a patent license agreement for Deuruxolitinib from Sun Pharmaceutical Industries
  • 15 May 2023 Concert Pharmaceuticals completes a phase II trial for Alopecia areata in USA (PO) (NCT04784533)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top